A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-22. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
The Wisconsin Sleep Cohort Study estimated in 1993 that roughly one in every 15 Americans was affected by at least moderate sleep apnea. It also estimated that in middle-age as many as 9% of women and 24% of men were affected, undiagnosed and untreated. The costs of untreated sleep apnea reach further than just health issues. It is estimated that in the U.S., the average untreated sleep apnea patient's annual health care costs $1,336 more than an individual without sleep apnea. This may cause $3.4 billion/year in additional medical costs. Whether medical cost savings occur with treatment of sleep apnea remains to be determined.
== History == Scott Reismanis, a website developer from Melbourne, Australia, first pursued web development as a hobby, creating two websites dedicated to video games. Afterwards, he purchased the ChaosRealm.com domain and formed the Realm Network. The network comprised over twenty websites, one of which was ModDB's predecessor, ModRealm. Launched in 1998, ModRealm was initially dedicated to Counter-Strike cheat codes before becoming a modding website. The website became defunct in December 2001, when its network was shut down after its hosting service, Playnet, filed for bankruptcy. Reismanis was motivated to start a new website by the difficulty of searching for mods on the then-dominant search engine, AltaVista, much less mods released to the public. He began ModDB's development in January 2002, following IMDb's structure in the process. The website was launched as Mod Database in June 2002. It differed from his earlier websites in that its articles were managed by the community, not only the website's founder. By January 2005, ModDB listed 49,539 members and 2,191 mods. In 2006, the ModDB team launched AddonDB, whose aim was to list additional content for games not applicable under the category of game modifications. This includes models, skins and maps. Just one year into service, it was merged into ModDB.
== Honors and awards == American Heart Association Basic Research Prize (1993) William B. Coley Award for Distinguished Research in Basic and Tumor Immunology (1995) Member of the National Academy of Sciences (1996) Member of the National Academy of Medicine (2023) Fellow of the American Academy of Arts and Sciences (2001) Crafoord Prize in Polyarthritis (2004) Guggenheim Fellowship (2004) Fellow of the American Association for the Advancement of Science (2013) AAI-Life Technologies Meritorious Career Award (now AAI-Thermo Fisher Meritorious Career Award), American Association of Immunologists (2014) Henry M. Stratton Medal, American Society of Hematology (2014) Canada Gairdner International Award (2019) Albert Lasker Award for Basic Medical Research (2022) Robert Koch Prize (2023) Biophysical Society Founders Award (2022) The Protein Society Stein & Moore Award (2025) Fellow of the National Academy of Inventors (2025) Included in Forbes’ 250: America’s Greatest Innovators list (2026) Selected to receive the American Society for Biochemistry and Molecular Biology’s Bert and Natalie Vallee Award in Biomedical Science (2027) He was a Phi Beta Kappa graduate from the University of California, Berkeley.
Sources: en.wikipedia.org
== Structure and membership == Article 10.(b) of the Draft Constitutional Declaration defines the Sovereignty Council to consist of five civilians chosen by the FFC, five military chosen by the TMC, and a civilian "selected by agreement" between the FFC and TMC. Under Article 10.(c) of the Draft Constitutional Declaration, for the first 21 months of the 39-month transitional period defined by the document, the chair of the Sovereignty Council was to be chosen by the five military members of the council. For the following 18 months, the chair was to be chosen by the five civilian members selected by the FFC. The military membership of the Sovereignty Council included General Abdel Fattah al-Burhan, General Hemedti, Lieutenant-General Yasser al-Atta, General Shams al-Din Khabbashi and Major-General Ibrahim Jabir Karim. Hemedti has been the deputy chairman of the Sovereignty Council in the past. The five civilians chosen by the FFC are Aisha Musa el-Said of the National Gathering Initiative; Siddiq Tawer, a prominent member of the Arab Socialist Ba'ath Party – Region of Sudan (and thereby a member of the National Consensus Forces) from the Nuba Mountains in South Kordofan; Mohamed al-Faki Suleiman of the Unionist Gathering from Northern Sudan; Hassan Sheikh Idris (or Hassan Mohamed Idris), a prominent member of the National Umma Party (and thereby a member of Sudan Call) from Kassala; and Mohammed Hassan Osman al-Ta'ishi of the Sudanese Professionals Association.
In 1960, the Grace Line, inspired by the pioneering efforts of Sea-Land Service, Matson Navigation, and Seatrain Lines, sought to begin containerizing its South American cargo operations by converting the conventional freighters Santa Eliana and Santa Leonor into fully cellular container ships. The effort was stymied by the opposition of longshoremen in New York and Venezuela, and the ships were repeatedly laid up idle and were ultimately sold to the domestic container line Sea-Land Service in 1964. In 1963 Grace made a second attempt to containerize its South American trade when it ordered the four M-class combination passenger-cargo ships Santa Magdalaena, Santa Maria, Santa Mariana, and Santa Mercedes with partial cellular holds, but they were no more successful as mixing conventional break-bulk cargo and containers in the same ship negated the operating economies that full containerization promised. In 1970, Grace Line was sold to Prudential Lines for $44.5 million, with the merged company renamed Prudential Grace Line. It was taken over by Delta Steamship Lines in 1978, thereby extinguishing the name Grace in ocean shipping. Subsequently, Delta Steamship Lines was acquired and consolidated by Crowley Maritime in 1982.
The Spanish American wars of independence (Spanish: Guerras de independencia hispanoamericanas) were a series of conflicts across the Spanish Empire in the early 19th century. They began shortly after the outbreak of the Peninsular War and formed part of the broader Napoleonic Wars. The process unfolded in two main phases. First, the Spanish Monarchy broke up, beginning in Spain in 1808 with the invasion by the French Empire, the Spanish uprising against the Bonapartes, the vacancy of the throne, and the emergence of juntas later replicated in America. This unfolded as it did because the monarchy's basic cellular structure was the cabildo (town council, or ayuntamiento). Second, attempts at reconstruction failed and became a war in their own right: Cádiz sought a pan-Hispanic state, Ferdinand VII sought to restore the Crown returned to him by Napoleon, and in the Americas Bolívar, Iturbide and others tried to build large federations or empires. The result was the fragmentation of the Hispanic world into multiple states that largely reconstituted the old Spanish administrative boundaries under uti possidetis. The conflicts were multilateral, involving factions grouped into two camps: Royalists, who favoured continued Spanish rule, and Patriots, who supported independent monarchies or republics separate from Spain and from one another. They led to the independence of most of Spanish America and, through Balkanization, to Hispanic America. Defined strictly by military campaigns, they ran from the 1809 Battle of Chacaltaya (Bolivia) to the 1829 Battle of Tampico (Mexico).
=== Xie === In contrast to the majority of other functional entities, xuè or xiě (血, "blood") is correlated with a physical form – the red liquid running in the blood vessels. Its concept is, nevertheless, defined by its functions: nourishing all parts and tissues of the body, safeguarding an adequate degree of moisture, and sustaining and soothing both consciousness and sleep. Typical symptoms of a lack of xiě (usually termed "blood vacuity" [血虚; xiě xū]) are described as: Pale-white or withered-yellow complexion, dizziness, flowery vision, palpitations, insomnia, numbness of the extremities; pale tongue; "fine" pulse.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.